北京脑科学与类脑研究所：发现抑郁症治疗新机制，有望颠覆传统治疗手段

Core Insights - Depression is a significant challenge in clinical psychiatry, as highlighted by the Beijing Brain Science and Brain-like Research Institute's recent findings [1] - The study published in Nature identifies adenosine signaling as a key pathway for the rapid antidepressant effects of ketamine and electroconvulsive therapy (ECT) [1] - The research proposes an "intermittent hypoxia intervention" (aIH) to safely and controllably induce adenosine release in the brain, leading to significant antidepressant effects [1] Summary by Categories Research Findings - The study confirms that adenosine signaling is a common mechanism underlying the rapid antidepressant actions of both ketamine and ECT [1] - This discovery enhances the understanding of rapid antidepressant mechanisms and provides a solid theoretical basis for developing new generation antidepressant strategies with fewer side effects [1] Implications for Treatment - The findings suggest potential for developing small molecule drugs and non-drug interventions targeting adenosine signaling [1] - The research opens avenues for safer and more effective treatment options for depression, addressing a critical need in mental health care [1]